Share This Page
Drug Price Trends for GS MUCUS ER
✉ Email this page to a colleague
Average Pharmacy Cost for GS MUCUS ER
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GS MUCUS ER 600 MG CAPLET | 00113-2023-60 | 0.34521 | EACH | 2024-12-18 |
| GS MUCUS ER 600 MG CAPLET | 00113-2023-60 | 0.39928 | EACH | 2024-11-20 |
| GS MUCUS ER 600 MG CAPLET | 00113-2023-60 | 0.32011 | EACH | 2024-10-23 |
| GS MUCUS ER 600 MG CAPLET | 00113-2023-60 | 0.35791 | EACH | 2024-09-18 |
| GS MUCUS ER 600 MG CAPLET | 00113-2023-60 | 0.30672 | EACH | 2024-08-21 |
| GS MUCUS ER 600 MG CAPLET | 00113-2023-60 | 0.34840 | EACH | 2024-07-17 |
| GS MUCUS ER 600 MG CAPLET | 00113-2023-60 | 0.35001 | EACH | 2024-06-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Expectorant Drugs: A Focus on Guaifenesin (GS MUCUS ER)
Introduction to Expectorant Drugs
Expectorant drugs, such as guaifenesin, are crucial in managing respiratory conditions by helping to thin and loosen mucus, making it easier to expel. These drugs are particularly important in the treatment of coughs, bronchitis, and other respiratory ailments.
Market Size and Growth Projections
The expectorant drugs market, which includes guaifenesin, is anticipated to experience significant growth over the coming years.
- Global Market Size: The global expectorant drugs market was valued at approximately $17,648.2 million in 2024 and is projected to reach $38,455.4 million by 2034, growing at a CAGR of 4.3% during this period[5].
- Segmented Market: The guaifenesin market, a subset of the expectorant drugs market, is forecasted to reach $95 million by 2027, growing at a CAGR of around 3.1% from 2022 to 2027[3].
Regional Market Analysis
North America
North America is expected to dominate the expectorant drugs market due to several factors:
- High Prevalence of Respiratory Diseases: The region has a high incidence of respiratory diseases such as COPD, asthma, and the common cold, which drives the demand for expectorants[1].
- Presence of Key Players: Major pharmaceutical companies like Merck KGaA, Perrigo Company plc, and Johnson & Johnson Private Limited operate in this region[1].
- R&D Expenditure: Significant research and development activities in the pharmaceutical sector contribute to market growth[5].
Asia Pacific
The Asia Pacific region is identified as the fastest-growing market for expectorant drugs:
- Increasing Demand: Rising cases of respiratory illnesses and the growing healthcare infrastructure in countries like India and China are driving the demand for expectorants[1][3].
Key Drivers of Market Growth
COVID-19 Impact
The COVID-19 pandemic has significantly impacted the demand for expectorant drugs:
- Surge in Demand: The initial outbreak led to an increased demand for OTC expectorants as people sought relief from respiratory symptoms associated with COVID-19[1].
- Post-COVID Complications: Conditions like lung fibrosis and COPD, which require expectorant drugs for management, have further boosted market growth[1].
Healthcare Infrastructure
The advancement in hospital infrastructure and the growth in pharmaceutical production post-COVID-19 have contributed to the increasing demand for guaifenesin and other expectorant drugs:
- Hospital Sector Growth: The hospital sector in countries like India is expected to rise significantly, driving the demand for pharmaceutical medications, including expectorants[3].
Product and Application Analysis
Guaifenesin
Guaifenesin is a widely used expectorant:
- Forms and Applications: It is available in various forms such as tablets, dissolving granules, syrup, and extended-release tablets. It is used in treating acute rhinosinusitis, cough, chest congestion, and other respiratory issues[3][4].
- Combination Therapies: Often combined with cough suppressants like dextromethorphan and decongestants, guaifenesin is a key component in many over-the-counter and prescription medications[3].
Price Projections and Market Dynamics
Market Value and CAGR
- The global guaifenesin market is expected to grow at a CAGR of around 3.1% from 2022 to 2027, reaching a market size of $95 million by 2027[3].
- The broader expectorant drugs market is projected to grow at a CAGR of 4.3% from 2024 to 2034, reaching $38,455.4 million by 2034[5].
Pricing Factors
The pricing of guaifenesin and other expectorant drugs can be influenced by several factors:
- Production Costs: The cost of raw materials, manufacturing, and distribution can impact the final product price.
- Regulatory Environment: Government initiatives and regulations can affect the pricing and availability of these drugs.
- Market Competition: The presence of key players and the availability of substitutes can drive competitive pricing[1][3].
Challenges and Opportunities
Availability of Substitutes
One of the major challenges facing the guaifenesin market is the availability of substitutes:
- Alternative Treatments: The presence of other expectorants and alternative treatments can reduce the demand for guaifenesin[3].
Growing Demand in Hospitals
The increasing demand for guaifenesin in hospitals presents a significant opportunity:
- Hospital Infrastructure Growth: The expansion of hospital infrastructure and the growing need for pharmaceutical medications in hospitals are driving the demand for guaifenesin[3].
Key Takeaways
- Market Growth: The expectorant drugs market, including guaifenesin, is expected to grow significantly over the next decade.
- Regional Dominance: North America is expected to dominate the market, while the Asia Pacific region will experience the fastest growth.
- COVID-19 Impact: The pandemic has accelerated the demand for expectorant drugs due to increased respiratory health concerns.
- Healthcare Infrastructure: Advancements in hospital infrastructure and pharmaceutical production are key drivers of market growth.
FAQs
What is the projected market size of the global expectorant drugs market by 2034?
The global expectorant drugs market is projected to reach $38,455.4 million by 2034[5].
Which region is expected to dominate the expectorant drugs market?
North America is expected to dominate the expectorant drugs market due to the high prevalence of respiratory diseases and the presence of key players[1].
What is the CAGR of the guaifenesin market from 2022 to 2027?
The guaifenesin market is expected to grow at a CAGR of around 3.1% from 2022 to 2027[3].
How has the COVID-19 pandemic impacted the demand for expectorant drugs?
The COVID-19 pandemic led to a surge in demand for OTC expectorants and highlighted the importance of maintaining good respiratory health, driving market growth[1].
What are the major forms and applications of guaifenesin?
Guaifenesin is available in forms such as tablets, dissolving granules, syrup, and extended-release tablets, and is used in treating acute rhinosinusitis, cough, chest congestion, and other respiratory issues[3][4].
Sources
- Mordor Intelligence: Expectorant Drugs Market Size & Share Analysis[1]
- IndustryARC: Guaifenesin Market Size Report, 2022-2027[3]
- Future Market Insights: Global Expectorant Drugs Market Growth Projection 2024-2034[5]
- Davis Islands Pharmacy: GNP MUCUS RELIEF ER 600MG TAB 20CT[4]
More… ↓
